+34 679 490 537info@nanbiosis.com

Nanbiosis

U1. Protein Production Platform Unit (PPP)

Ciber bbn

U1. Protein Production Platform (PPP)

U1. PPP logo   IBB UAB
Order request

Custom Gallery: images not found

Description

The PPP Unit is at the Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB-UAB) and counts with the necessary facilities for the design, production and purification of recombinant proteins. This facility is coordinated by the Nanobiotechnology Group, leaded by Prof. Antonio Villaverde. It has both highly specialized personnel and the necessary equipment to offer an “tailored” service for the design, production and purification of recombinant proteins using both prokaryotic and eukaryotic expression systems. Its location allows this service to be linked with other complementary services available within the university (Cell Culture, Cytometry, Production of Antibodies, Microscopy, Proteomic, and Bioinformatic,X-ray crystallography, and the Microarray and Sequencing Services), as well as facilitating the management of subsequent uses of the produced protein.

Counts with a laboratory perfectly equipped for the bioproduction of proteins, other with all the necessary equipment for the molecular cloning, plus one lab for the purification and characterization, and finally one for cryopreservation.

The PPP Unit is also applying for the ISO9001 certification forstandard quality control system.

IQNet ISO 9001:2015 Certification PPP

AENOR ISO 9001:2015 Certification PPP

Active projects

TitleFundin: OrganismCall: Funding source Role
GA: 720942SMART FUNCTIONAL GLA-NANOFORMULATION FOR FABRY DISEASE – Smart-4-FabryUnión Europea (Comisión Europea)H2020-NMBP-2016-2017Coordinator
SAF2017-90810-REDIStrategic Promotion and coordinated management of Nanbiosis: Pronanbiosis IIAgencia Estatal de Investigación (AEI)Acciones de dinamización «REDES DE EXCELENCIA» -ICTS 2017Coordinator

Other projects

RefTitleFunding OrganismUnit Role
PI15/00272Design of intelligent nanoconjugates for the treatment of metastatic colorectal cancer.Instituto de Salud Carlos IIIParticipant
BIO2013-41019-PENGINEERING OF PROTEIN NANOPARTICLES FOR THE DIRECT DELIVERY OF THERAPEUTIC PROTEINS AND NUCLEIC ACIDSMINECOParticipant
2014SGR-132Basic and Applied MicrobiologyAGAURParticipant
BIO2016-76063-RDEVELOPMENT OF NONOSTRUCTURED PROTEIN TOXINS AND POISONS FOR THE TREATMENT OF CXCR4 + CANCERESMINECOWorking package
RTC-2014-2207-1TERARMET: Development of therapies for the treatment of rare congenital metabolic diseasesMINECOParticipant
Marato 416/C/2030TV32013-132031Genotoxic nanoparticles targeting colorectal cancer stem cellsMarato TV3Participant

Publications

2016

  • Corchero J.L.. Eukaryotic aggresomes: from a model of conformational diseases to an emerging type of immobilized biocatalyzers. Applied Microbiology and Biotechnology. 2016;100(2):559-569.
  • Saccardo P., Corchero J.L., Ferrer-Miralles N.. Tools to cope with difficult-to-express proteins. Applied Microbiology and Biotechnology. 2016;:1-9.
  • Torrealba D., Seras-Franzoso J., Mamat U., Wilke K., Villaverde A., Roher N. et al. Complex particulate biomaterials as immunostimulant-delivery platforms. PLoS ONE. 2016;11(10)
  • Cano-Garrido O., Sanchez-Chardi A., Pares S., Giro I., Tatkiewicz W.I., Ferrer-Miralles N. et al. Functional protein-based nanomaterial produced in microorganisms recognized as safe: A new platform for biotechnology. Acta Biomaterialia. 2016;43:230-239.
  • Serna N., Cespedes M.V., Saccardo P., Xu Z., Unzueta U., Alamo P. et al. Rational engineering of single-chain polypeptides into protein-only, BBB-targeted nanoparticles. Nanomedicine: Nanotechnology, Biology, and Medicine. 2016;12(5):1241-1251.
  • Rueda F., Gasser B., Sanchez-Chardi A., Roldan M., Villegas S., Puxbaum V. et al. Functional inclusion bodies produced in the yeast Pichia pastoris. Microbial Cell Factories. 2016;15(1)
  • Cabrera I., Abasolo I., Corchero J.L., Elizondo E., Gil P.R., Moreno E. et al. α-Galactosidase-A Loaded-Nanoliposomes with Enhanced Enzymatic Activity and Intracellular Penetration. Advanced Healthcare Materials. 2016;5(7):829-840.
  • Céspedes MV, Unzueta U, Álamo P, Gallardo A, Sala R, Casanova I et al. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4+ colorectal cancer models.Nanomedicine : nanotechnology, biology, and medicine. 2016;12(7)
  • Giannotti M.I., Abasolo I., Oliva M., Andrade F., Garcia-Aranda N., Melgarejo M. et al. Highly Versatile Polyelectrolyte Complexes for Improving the Enzyme Replacement Therapy of Lysosomal Storage Disorders. ACS Applied Materials and Interfaces. 2016;8(39):25741-25752.

News U1

10 Feb

A new smart drug that finds and kills metastasis cells could be applied in 23 types of cancer

Researchers of two CIBER-BBN Units of the ICTS NANBIOSIS  U18 Nanotoxicology Unit at Hospital Sant Pau. and U1, Protein Production Platform (PPP), at the  Institute of Biotechnology and biomedicine of the Autonomous University of Barcelona (IBB–UAB), led by Prof Ramón Mangues, have developed a new drug that selectively removes metastatic stem cells, inducing a powerful metastasis prevention effect. Besides the participation of the “NANBIOSIS” ICTS Units U1 Protein Production Platform where Protein production was partially performed and U18 Nantoxicology Unit where Biodistribution studies were performed, all in vivo experiments were performed by the Unit 20 In Vivo Experimental Platform of CIBER[...]

04 Feb

NANBIOSIS research to fight cancer

Twenty years ago, the 4 February was declared World Cancer Day with the global challenge of cancer would not be forgotten. Since then, huge progress has been made to understand, prevent, diagnose, and treat cancer. NANBIOSIS as an ICTS (Singular Scientific and Technical infrastructures) for biomedical research plays a very important role in the fight against cancer. Some examples of the work carried out during the last year, are bellow: Unit 20 of NANBIOSIS  at VHIR, works in several proyects reletaed to cancer as  H2020-NoCanTher: magnetic nanoparticles against pancreatic cancer through the use of hyperthermia combined with conventional treatment. H2020-Target-4-Cancer: nanotherapy based on polymeric micelles directed against[...]

30 Dec

A step forward for the design of multifunctional protein nanomaterials for cancer therapies

Researchers of NANBIOSIS Unit 1 and NANBIOSIS Unit 18, led by Prof Antoni Villaverde have published the article at the prestigious scintific magazine titled Collaborative membrane activity and receptor-dependent tumor cell targeting for precise nanoparticle delivery in CXCR4+ colorectal cancer The researchers have shown that the combination of cell-penetrating and tumor cell-targeting peptides dramatically enhances precise tumor accumulation of protein-only nanoparticles intended for selective drug delivery, in mouse models of human colorectal cancer. This fact is a step forward for the rational design of multifunctional protein nanomaterials for improved cancer therapies. Protein production has been partially performed by the  ICTS NANBIOSIS U1, Protein Production Platform[...]

27 Dec

Why the poor biodistribution so far reached by tumor-targeted medicines?

Cell-selective targeting is expected to enhance effectiveness and minimize side effects of cytotoxic agents. Functionalization of drugs or drug nanoconjugates with specific cell ligands allows receptor-mediated selective cell delivery. However, it is unclear whether the incorporation of an efficient ligand into a drug vehicle is sufficient to ensure proper biodistribution upon systemic administration, and also at which extent biophysical properties of the vehicle may contribute to the accumulation in target tissues during active targeting. To approach this issue, structural robustness of self-assembling, protein-only nanoparticles targeted to the tumoral marker CXCR4 is compromised by reducing the number of histidine residues (from[...]

23 Dec

Artificial inclusion bodies for controlled drug release

Researchers from NANBIOSIS-CIBER-BBN have developed a new type of protein biomaterial that allows a continuous release over time of therapeutic proteins when administered subcutaneously in laboratory animals. These results are the result of the stable scientific collaboration between the researchers of NANBIOSIS Units 1 Protein Production Platform (PPP)and 18 Nanotoxicology Unit, led by Toni Villaverde and Ramón Mangues at the Institute of Biotechnology and Biomedicine of the Autonomous University of Barcelona (IBB-UAB) and the Institut About the Hospital de Sant Pau and has had the participation of the Institute of Biological and Technological Research of the National University of Córdoba-CONICET,[...]

17 Dec

A new method simple and efficient for the preparation of Oligonucleotide-protein conjugates

Oligonucleotide-protein conjugates have important applications in biomedicine. Four units of NANBIOSIS have collaborated to come across with more simple and efficient methods for the preparation of these conjugates. In the publication of the research results, a new method is described in which a bifunctional linker is attached to thiol-oligonucleotide to generate a reactive intermediate that is used to link to the protein. Having similar conjugation efficacy compared with the classical method in which the bifunctional linker is attached first to the protein, this new approach produces significantly more active conjugates with higher batch to batch reproducibility. In a second approach,[...]

16 Dec

A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models

Researchers of NANBIOSIS Unit 1 and NANBIOSIS Unit 18,  led by Ramón Mangues, have published the article titled CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models . One-third of diffuse large B-cell lymphoma patients are refractory to initial treatment or relapse after rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone chemotherapy. In these patients, CXCR4 overexpression (CXCR4+) associates with lower overall and disease-free survival. Nanomedicine pursues active targeting to selectively deliver antitumor agents to cancer cells, a novel approach that promises to revolutionize therapy by dramatically increasing drug concentration in target tumor cells. In the study carried out[...]

08 Nov

Non-Hodgkin lymphoma treatment with protein nanoparticles

A study result of collaboration between researchers of two NANBIOSIS units managed to produce a potent antitumor effect in an animal model with non-Hodgkin lymphoma A non-Hodgkin’s lymphoma, NHL is a cancer that starts in white blood cells called lymphocytes, which are part of the body’s immune system. Lymphoma. NHL is a term that’s used for many different types of lymphoma that share some characteristics.  The most prevalent type of non-Hodgkin lymphoma is called diffuse large B-cell lymphoma (LDCGB). Although there are treatments for this pathology, there are non-responders. This nanoparticle can be developed as a nanopharmaceutical, in order to introduce a new treatment, whic[...]

U1-Protein Production Platform - PPP
Read More

U27. High Performance Computing

Ciber bbn

U27. High Performance Computing

  • Scientific Director: Prof. Pablo Laguna laguna@unizar.es
  • Scientific Coordinator: Alfonso Marquina amarq@unizar.es
  • Entities: I3A-Universidad de Zaragoza.
  • Address: C/Mariano Esquillor s/n 50018, Zaragoza
  • Phone: +34 976 76 27 07
  • Web: I3A-UZ

Nanabiosis-logo Universidad de Zarargoza-U9-U13-U27.

Order request

Description

Located at the Aragon Institute of Engineering Research (I3A), an Interdisciplinary University Research Institute specialized in engineering of the University of Zaragoza, this HPC service counts with a conditioned room to host a cluster of computers that allows remote access for High Performance Computing, massive storage and different software applications for the research in four divisions: Biomedical Engineering, Information and Communications Technologies Division, Processes and Recycling Division and Industrial Technology Division. This Unit is coordinated by Prof. Pablo Laguna, PI of the Biomedical Signal Interpretation & Computational Simulation Groups (BSICoS).

Active projects

Title Fundin: Organism Call: Funding source Role
SAF2017-90810-REDI Strategic Promotion and coordinated management of Nanbiosis: Pronanbiosis II Agencia Estatal de Investigación (AEI) Acciones de dinamización «REDES DE EXCELENCIA»
-ICTS 2017
Coordinator

Other projects

Ref Title Funding Organism Unit Role
T96 BIOMEDICAL SIGNAL INTERPRETATION & COMPUTATIONAL SIMULATION DGA Participant
UZCUD2016-TEC-03 Optimization of a submersible device for the monitoring of the photoplestimográfica signal CUD Participant
DPI2016-75458-R MULTI-SCALE PHYSIOLOGY-DRIVEN COMPUTATIONAL TOOLS TO ASSIST IN THE ASSESSMENT AND MANAGEMENT OF CARDIAC DYSFUNCTIONS MINECO Participant
TIN2013-41998-R THE AUTONOMOUS NERVOUS SYSTEM AS A MODULATOR OF CARDIAC FUNCTION: INTEGRAL RESEARCH THROUGH SIGNAL PROCESSING AND COMPUTATIONAL MODELING MINECO Participant

Publications

2016

  • Laguna P., Martinez Cortes J.P., Pueyo E.. Techniques for Ventricular Repolarization Instability Assessment from the ECG. Proceedings of the IEEE. 2016;104(2):392-415.
  • Pueyo E., Dangerfield C.E., Britton O.J., Virag L., Kistamas K., Szentandrassy N. et al. Experimentally-based computational investigation into beat-to-beat variability in ventricular repolarization and its response to ionic current inhibition. PLoS ONE. 2016;11(3):-.
  • Romero D., Martinez J.P., Laguna P., Pueyo E.. Ischemia detection from morphological QRS angle changes. Physiological Measurement. 2016;37(7):1004-1023.
  • Vicente J., Laguna P., Bartra A., Bailon R.. Drowsiness detection using heart rate variability. Medical and Biological Engineering and Computing. 2016;:1-11.
  • Alcaine A., De Groot N.M.S., Laguna P., Martinez J.P., Houben R.P.M.. Spatiotemporal model-based estimation of high-density atrial fibrillation activation maps. Digital Signal Processing: A Review Journal. 2016;54:64-74.
  • Bolea J., Pueyo E., Orini M., Bailon R.. Influence of heart rate in non-linear HRV indices as a sampling rate effect evaluated on supine and standing. Frontiers in Physiology. 2016;7(NOV):-.
  • Ortigosa N., Rodriguez-Lopez M., Bailon R., Sarvari S.I., Sitges M., Gratacos E. et al. Heart morphology differences induced by intrauterine growth restriction and preterm birth measured on the ECG at preadolescent age. Journal of Electrocardiology. 2016;:-.
  • Hernando A., Lazaro J., Gil E., Arza A., Garzon J.M., Lopez-Anton R. et al. Inclusion of Respiratory Frequency Information in Heart Rate Variability Analysis for Stress Assessment. IEEE Journal of Biomedical and Health Informatics. 2016;20(4):1016-1025.

News U27

12 Nov

Understanding between doctors and engineers: essential to advance in health

Pablo Laguna Lasaosa, New Director of I3A and scientific director of NANBIOSIS U27 High Performance Computing talks about Biomedical Engineering in the radio programm “La Brujula de Aragón” @OndaCero_ Professor of signal and communications, expert of biomedical signals in the cardio vascular domain, Pablo Laguna talks about engineering today and how the relative weight of engineering is nowadays repesented by the information engineering, computer engineering and the treatment of information to be applyed in different domains, new materials and new ways of addressing and solving problems. For the recently appointed director of the I3A, there is an opportunity in this[...]

11 Nov

Pablo Laguna, new director of the Aragon Engineering Research Institute

Pablo Laguna Lasaosa, Scientific Director of Unit 27 High Performance Computing has been elected new director of the Aragon Engineering Research Institute (I3A). Pablo Laguna Lasaosa, Professor of Signal Theory and Communications at the School of Engineering and Architecture (EINA) of the University of Zaragoza, develops its research activity in the field of signal processing, particularly applied to biomedical applications. Laguna is co-author of more than 150 research articles on this subject, more than 10 book chapters, more than 300 international conference documents and director of 15 doctoral theses. He has led a good number of projects on the interpretation[...]

16 Aug

The University of Zaragoza, in the elite of the 500 best universities in the world

The Academic Ranking of World Universities (ARWU), known as Shanghai Ranking, which was made public on August 15, once again places the University of Zaragoza among the elite of the 500 best universities in the world. This indicator organizes up to 20,000 university centers worldwide. Among the keys that have been able to positively influence the results of the research, according to the Vice Chancellor for Prospect, Sustainability and Infrastructure of the University of Zaragoza, Francisco Serón, are the increase in public campus funding for four years as well as the quality of their Scientists. The University of Zaragoza houses[...]

29 Jul

Making the most from Signals in Biomedical applications.

Last week took place on Berlin the EMB Conference 2019, (the 41st  International Engineering in Medicine and Biology Conference) with the overarching theme “Biomedical engineering ranging from wellness to intensive care” counting with plenary keynotes from leading academic and industrial scientists, who presented aspects of innovation and translational engineering in biomedicine. Pablo Laguna, Scientific Director of NANBIOSIS Unit 27, from CIBER-BBN and I3A-UZ, was invited to give a talk on the topic “Phisiologically Driven Biomedical Signal Processing: making the most of Signals” Pablo Laguna has co-authored more than 150 research papers on this topic, over 300 international conference papers, and has advise 15 Ph.D[...]

31 May

NANBIOSIS U27 propose a mew method for assessing nonlinear cardiorespiratory interactions

Researches of NANBIOSIS Unit 27 High Performance Computing, S. Kontaxis, J. Lázaro, E. Gil, P. Laguna, and R. Bailón are the authors of an article recently published by IEEE Transactions Biomedical Engineering Alternations of cardiorespiratory interactions are related to Autonomic Nervous System (ANS) dysfunction and physiological regulation of the Heart Rate Variability (HRV) in cardiovascular diseases. In this study, a method for assessing nonlinear cardiorespiratory interactions is proposed, quantifying the Quadratic Phase Coupling (QPC) between respiration and HRV. Quadratic cardiorespiratory couplings are studied during a tilt table test protocol on young healthy subjects. Results show a significant reduction of QPC[...]

24 May

Quantification of Ventricular Repolarization Variation for Sudden Cardiac Death Risk Stratification in Atrial Fibrillation

ATRIAL fibrillation (AF) is the most prevalent sustained arrhythmia and it has become one of the most important public health issues in developed countries. It is expected to double its incidence by 2030 [1], [2], representing the major cause of hospitalizations in elderlies (≥65 years), together with chronic heart failure Alba Martín-Yebra and Juan Pablo Martínez, scientists of NANBIOSIS U27 High Performance Computing, have led the research that proves that it is possible to stratity AF patients at risk of sudden cardiac death (SCD) what could help cardologists to implement better solutions. The computation was performed by the ICTS NANBIOSIS,[...]

05 Sep

NANBIOSIS Unit 27 at VPH2018: VIRTUAL PHYSIOLOGICAL HUMAN 2018

The VPH Conference 2018 is taking place in Zaragoza 5-7 September offering an exciting program of state-of-the art science & engineering in computational (bio)medicine, ranging from foundational research on multiscale modelling of human (patho) physiology, via underpinning research on data science and infrastructures for the virtual physiological human, to clinical applications with participation of NANBIOSIS U27. High Performance Computing Esther Pueyo  is charing the Session 3A: Cardiovascular modeling: from simulation to clinical outcome, Some of the outcomes are presented by Jesús Fernández-Bes: A Bayesian Filtering methodology to identify key drivers of ventricular repolarization variability (Jesus Fernandez-Bes, David Adolfo Sampedro-Puente and Esther Pueyo)  Virtual Physiologica[...]

26 Jun

Esther Pueyo, NANBIOSIS U 27, at the 3rd Barcelona VPH Summer School

The 3rd VPH Summer School was held in Barcelona, ​​on June 18-22, 2018.  The VPH Summer School series is co-organized by the Barcelona MedTEch – Pompeu Fabra University and by the Virtual Physiological Human Institute. The Summer School provides a thorough overview and hands-on experience in state-of-the-art Virtual Physiological Human (VPH) research. The event is dedicated to PhD students and junior postdocs who seeks cross dissemination and a guided experience through the use of computer models and simulations to tackle specific clinical problems, not only engineers but also biomedical scientists and medical doctors with an interest in computer modeling and[...]

U27- High Performance Computing
Read More